Leading the Way as a Premier Cardiac and Diabetic Pharma Company in India-Arlak Corazon

India's pharmaceutical sector is pivotal in addressing chronic conditions like cardiovascular diseases and diabetes, which affect millions. Entrepreneurs and healthcare professionals seek reliable partners in this niche. Arlak Corazon stands out as a dedicated Cardiac and Diabetic Pharma Company in India, delivering innovative, high-quality formulations that enhance patient outcomes while offering lucrative business avenues.

About Us

Arlak Corazon, a dynamic division of Arlak Biotech, is a rapidly growing Cardiac and Diabetic Pharma Company in India based in Zirakpur, Punjab. We specialize in transforming cardiovascular and diabetic treatments through clinically tested, groundbreaking therapeutics. Our ISO, WHO, GMP, and FDA-compliant operations ensure safe, effective, and affordable medicines. With an experienced R&D team and state-of-the-art manufacturing plants, we focus on purity, efficacy, and accessibility. Committed to supporting the Indian healthcare system, we provide lifesaving formulations that meet stringent quality standards, building trust among professionals and patients alike.

Our Products

Arlak Corazon offers a comprehensive portfolio in various dosage forms to address cardiac and diabetic needs effectively.

• Tablets — Convenient oral solids covering beta-blockers, ACE inhibitors, biguanides, and sulfonylureas for daily management of heart conditions and blood sugar control.
• Injections — Rapid-action injectables, including insulin variants and certain cardiac therapies, produced in dedicated facilities for critical care.
• Capsules — Encapsulated options for precise dosing, featuring cholesterol-lowering agents and thiazolidinediones.
• Softgel Capsules — Advanced softgels for enhanced bioavailability, often used in nutritional supplements and specific diabetic formulations.

All products use 100% biologically active ingredients sourced from certified vendors, undergoing rigorous testing for potency and safety.

Business Opportunity

Third Party Manufacturing

We provide WHO, ISO, and GMP-certified third-party manufacturing services across multiple plants, including facilities for injectables, tablets, capsules, and more. This allows brands to outsource production with assured quality, minimal investment, and focus on marketing, ensuring timely delivery and compliance.

Our Cardiac Diabetic Product Range

Our range is meticulously developed with input from top cardiologists and endocrinologists.

Exclusive Cardiac Medicine Range

This includes beta-blockers, vasodilators, anticoagulants, calcium channel blockers, diuretics, antiplatelet agents, and more—to manage heart failure, hypertension, and cholesterol effectively.

Precise Quality Diabetic Medicine Range

Covering insulin, biguanides, DPP-4 inhibitors, SGLT2 inhibitors, alpha-glucosidase inhibitors, and others—for comprehensive control of Type 1 and Type 2 diabetes, along with related complications.

Partner for Monopoly-Based Cardiac Diabetic PCD Pharma Franchise

Arlak Corazon offers monopoly-based PCD Pharma Franchise opportunities, granting exclusive rights in designated territories. Partners benefit from reduced competition, higher profit margins (20-30%), free promotional tools (MR bags, visual aids, samples), attractive packaging, and PAN-India timely delivery. This model supports flexible investment and strong market penetration in the high-demand cardiac-diabetic segment.

Why Choose Us for Pharma Business

As a leading Cardiac and Diabetic Pharma Company in India, we provide monopoly rights, exciting incentives, robust logistics, and a wide in-demand portfolio. Our ethical practices, innovative approach, and dedicated support ensure long-term growth, patient safety, and professional trust—making us the preferred partner for franchisees and manufacturers.

Conclusion

Arlak Corazon exemplifies excellence as a specialized Cardiac and Diabetic Pharma Company in India, blending quality manufacturing, innovative products, and rewarding business models. Whether through third-party services or monopoly franchises, we empower partners to contribute to better health outcomes while achieving sustainable success. Join us to be part of this transformative journey in cardiovascular and diabetic care.